In vitro and in vivo activity of NY-198, a new difluorinated quinolone.
about
In vitro antibacterial activity of Q-35, a new fluoroquinoloneInhibition by quinolones of DNA gyrase from Staphylococcus aureus.In vitro and in vivo antibacterial activities of T-3262, a new fluoroquinolone.E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens.Lomefloxacin pharmacokinetics in subjects with normal and impaired renal functionPharmacokinetics of lomefloxacin in healthy volunteers: comparison of 400 milligrams once daily and 200 milligrams twice daily given orally for 5 days.Concentrations of oral lomefloxacin in serum and bronchial mucosa.Mechanism of action of lomefloxacin.Comparative in vitro and in vivo activities of six new monofluoroquinolone and difluoroquinolone 3-carboxylic acids with a 7-azetidin ring substituent.In vitro activity of DR-3355, an optically active ofloxacinIn vitro and in vivo antibacterial activities of E-4868, a new fluoroquinolone with a 7-azetidin ring substituent.Efficacy and safety of lomefloxacin on bacterial extraocular disease in the horse.Comparative study of penetration of lomefloxacin and ceftriaxone into transudative and exudative pleural effusionInterpretive criteria for susceptibility testing of CI-960 (PD127391, AM-1091), fleroxacin, lomefloxacin, and temafloxacin against Neisseria gonorrhoeae, including drug stability in GC agar medium.MIC and disk diffusion quality control guidelines for Neisseria gonorrhoeae susceptibility tests of cefdinir, cefetamet, CI-960, fleroxacin, lomefloxacin, and temafloxacinDevelopments in quinolones. Bacteriology, pharmacokinetics and initial clinical experience of several investigational quinolone derivatives.In vivo activity of HSR-903, a new fluoroquinolone, against respiratory pathogens.In vitro activity of HSR-903, a new quinolone.Intraprostatic distribution of lomefloxacin following multiple-dose administration.Enterohepatic circulation of NY-198, a new difluorinated quinolone, in rats.Inhibitory effects of quinolone antibacterial agents on gamma-aminobutyric acid binding to receptor sites in rat brain membranes.In vitro activity of lomefloxacin, a new quinolone antimicrobial agent, in comparison with those of other agents.In vitro activity of lomefloxacin (SC-47111; NY-198), a difluoroquinolone 3-carboxylic acid, compared with those of other quinolones.In vitro activities of lomefloxacin and temafloxacin against pathogens causing diarrheaInhibitory effects of quinolones on DNA gyrase of Escherichia coli and topoisomerase II of fetal calf thymus.Efficacy of NY-198 against experimental Legionnaires disease.Pharmacokinetics and tolerance of lomefloxacin after sequentially increasing oral doses.Pharmacokinetics and tissue penetration of orally administered lomefloxacinIn vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methoxy quinolone.Bioequivalence evaluation of lomefloxacin 400 mg tablets (Lomax versus Maxaquin in healthy human volunteers.In vitro activity of E-4868, a new trifluoroquinolone, compared to six similar compounds.Comparative in vitro activity of lomefloxacin, a new difluoroquinolone.Studies on the emergence of resistance to lomefloxacin in vitro.
P2860
Q34537973-16DBD8F4-8B0D-4D7C-9A33-D5BAD4C0AF25Q34566027-8E4A3A1A-ADD6-4187-8E81-15D10F76BB25Q34681603-E7CE70F0-8950-4AAC-8B61-B8607E795A15Q35111654-B7723C90-E2C5-435E-AEDC-12BE1B24B5DAQ35245293-6CD448A8-012C-4E5C-8A67-4ADED5577EFCQ35246804-87181947-5EFF-4215-A625-F58D4ADADE4DQ35258597-CEE2FAE7-AB7A-45E5-98E6-F492940882BDQ35260173-72B78D4B-5007-4BFF-AB52-5A62B629B5FBQ35284580-86126BD6-C395-42F7-9181-808112648031Q35563775-F6494A76-13C4-457B-8F85-13A9D2E63FDEQ35812502-D4FED8C5-F33E-493A-9667-43D80DC4A64AQ35924132-C4552A2D-63E4-4765-8ECA-F3AF6F3C12ADQ36758348-BED06D9B-2043-4EE6-B568-D7B32064C102Q37120085-40CA9024-7CBE-4B1D-865C-D8E712EBE823Q37120847-E4F58C4A-68A6-4A91-80EE-4F77DB5F1CDFQ38635746-D7330BD2-87A7-40E2-8932-CA04DC30628DQ39557374-212FBDCC-4F19-4E01-89C1-0D6B7408722FQ39784355-A4C822F4-050D-4341-96A3-6112CF982DC0Q39817359-8237F111-68B0-42BB-9768-D83FFDCC6698Q39817581-70EBEA13-1206-42F9-837C-8A421565BBC5Q39817630-5A3A2B91-CBE0-4015-861A-40AA5FD09359Q39818110-76127BF9-180E-4318-9A2A-0600C7A9DB41Q39818149-FDCB7E3D-0776-41B5-827B-B3FF44355AA8Q39819755-BEF29D2E-6E4D-418A-B525-975FF191DAEBQ39820165-272DAC54-9080-47A2-9FA1-924100A2F29CQ39832353-516DB82D-9C59-40AC-9AEF-884DF38FCFD3Q39832467-7C201B81-F74D-411B-BF92-2EC335D8A5D1Q39832474-68451162-497A-4601-ABF5-CE2301EB9035Q40285332-E0A44CD0-AAE8-4E49-9954-E96EE6578155Q51554291-4B896F90-EADC-46F0-91E6-834F2ACF0B55Q54248939-C3C93707-BA38-44B5-AC5E-F026B9307C50Q54361416-EBDCC890-7A8F-4B24-B746-24AFD89A388CQ54727002-2F44B4EA-51EA-415A-9771-87E2DE61888B
P2860
In vitro and in vivo activity of NY-198, a new difluorinated quinolone.
description
1987 nî lūn-bûn
@nan
1987年の論文
@ja
1987年論文
@yue
1987年論文
@zh-hant
1987年論文
@zh-hk
1987年論文
@zh-mo
1987年論文
@zh-tw
1987年论文
@wuu
1987年论文
@zh
1987年论文
@zh-cn
name
In vitro and in vivo activity of NY-198, a new difluorinated quinolone.
@en
type
label
In vitro and in vivo activity of NY-198, a new difluorinated quinolone.
@en
prefLabel
In vitro and in vivo activity of NY-198, a new difluorinated quinolone.
@en
P2093
P2860
P356
P1476
In vitro and in vivo activity of NY-198, a new difluorinated quinolone.
@en
P2093
P2860
P304
P356
10.1128/AAC.31.6.854
P407
P577
1987-06-01T00:00:00Z